European follow-up study for people with cystinosis
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study is a follow-up registry for people with cystinosis to track their health over time. It helps doctors learn more about the condition and how it affects daily life, without giving any new treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of cystinosis, which means either a blood test that measures cystine levels in white blood cells, an eye exam that shows cystine crystals, or genetic testing that confirms the diagnosis.
- You must be able to give written informed consent, either on your own or with the help of someone legally authorized to decide for you.
- There are no other restrictions, so even if you have other health conditions, you can still join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with confirmed cystinosis to better understand the condition. It mainly checks that you have the right diagnosis and can join voluntarily.
This study checks how people with cystinosis are doing long-term after finishing an earlier study medicine called CTNS-RD-04. It may help researchers understand the lasting effects and safety of that treatment over time.
This study tests a new medicine called TTI-0102 for cystinosis. It aims to see if it can help manage cystine levels in the body, which may reduce kidney and other organ damage.
This trial looks at the use of cysteamine to treat cystinosis, a rare inherited condition. It may help lower harmful cystine buildup in the body and improve outcomes, especially early in life.
This study looks at how cystinosis affects the energy centers (mitochondria) in your cells. It may help doctors understand how cysteamine treatment works in patients with kidney cystinosis.
This study looks at how cysteamine affects the bone health of people with nephropathic cystinosis, a rare genetic condition. It includes children and adults who are already taking cysteamine by mouth and will follow the study plan closely.
Hear when a new Cystinosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.